Why thyroid cancer trial monitoring is important in 2026
Thyroid cancer is the most common endocrine malignancy, with over 43,000 new cases diagnosed annually in the United States. While most well-differentiated thyroid cancers are curable with surgery and radioiodine, a significant subset of patients progress to radioiodine-refractory (RAIR) differentiated thyroid cancer, medullary thyroid cancer (MTC), or the rapidly lethal anaplastic thyroid cancer (ATC) — all representing active clinical development areas.
The thyroid cancer pipeline in 2026 is one of the most molecularly precise in oncology:
- RET inhibitors — selpercatinib (Retevmo) and pralsetinib (Gavreto) transformed RET-mutant MTC and RET-fusion thyroid cancer. Next-generation RET programs targeting acquired resistance are entering trials
- BRAF V600E inhibitors — dabrafenib/trametinib is approved for BRAF-mutant ATC; combination strategies expanding across DTC subtypes
- NTRK inhibitors — larotrectinib and entrectinib for NTRK-fusion thyroid cancer; resistance mechanisms under study
- Radioiodine redifferentiation — BRAF or MEK inhibition to restore radioiodine uptake in RAIR DTC is an active Phase 2 space
- Immunotherapy in ATC — pembrolizumab-based combinations showing activity in ATC; multiple programs ongoing
- Lenvatinib combinations — beyond the approved monotherapy setting, lenvatinib paired with IO is being explored across subtypes
Track every new thyroid cancer trial automatically
ClinicalTrials.gov updates daily. Our pipeline monitors it and delivers a clean digest every morning.
Start Free — No Credit CardWhat we monitor for thyroid cancer
Our system pulls from the ClinicalTrials.gov API every day. For a thyroid cancer watch profile, you can configure alerts for:
- Condition keywords: "thyroid cancer", "differentiated thyroid cancer", "papillary thyroid cancer", "medullary thyroid cancer", "anaplastic thyroid cancer", "follicular thyroid cancer"
- Drug/target keywords: "RET", "selpercatinib", "BRAF thyroid", "lenvatinib", "sorafenib", "cabozantinib", "radioiodine refractory" — any drug or target you're tracking
- Phase filter: Phase 1 for early competitive intelligence, Phase 2/3 for clinically meaningful competitive threats
- Sponsor type: Industry, academic, or all sponsors
- Status changes: New registrations, status updates, enrollment completions, and results postings
The molecularly-driven thyroid cancer pipeline
Thyroid cancer has become a showcase for precision oncology. The dominant oncogenic drivers — RET fusions/mutations, BRAF V600E, RAS mutations, NTRK fusions — are each targetable with approved or investigational agents. This creates a complex competitive landscape where multiple targeted agents compete across subtypes:
- MTC: RET-mutant MTC is now a required biomarker screen. Vandetanib and cabozantinib remain approved options; selpercatinib and pralsetinib have superior selectivity. Next-gen RET inhibitors in development include compounds targeting C481S and other resistance mutations
- RAIR DTC: Lenvatinib and sorafenib approved; multiple Phase 2 redifferentiation strategies (using BRAF, MEK, or PI3K inhibitors) aimed at restoring radioiodine sensitivity — this is an active and underserved space
- ATC: BRAF V600E-mutant ATC (approximately 45% of cases) can respond dramatically to dabrafenib+trametinib; IO combinations are the major active area for BRAF wild-type ATC
Who uses thyroid cancer trial monitoring
- Endocrine oncology BD teams — tracking competitor programs targeting RET, BRAF, NTRK for partnering or pipeline decisions
- Oncology investors — monitoring Phase 1/2 initiations for precision thyroid cancer programs
- Thyroid cancer patient advocacy groups — tracking new trial options for patients with advanced or refractory disease
- Endocrinologists and head-and-neck oncologists — staying current on available trials for RAIR DTC and MTC patients
- Academic researchers — monitoring competitive landscape and identifying collaboration opportunities
Stop missing new thyroid cancer trials
Set up your alert profile in 2 minutes. Daily digest to your inbox. Cancel anytime.
Get Free Thyroid Cancer Trial AlertsHow TrialNotify works
We run a direct API connection to ClinicalTrials.gov every morning, collecting all new and updated trials. Our matching engine compares each trial against your profile — condition keywords, drug targets, phase, sponsor type, and study status. Only relevant trials reach your inbox.
Your daily digest includes: trial title, phase, sponsor, current status, enrollment target, primary endpoint, and a direct link to the ClinicalTrials.gov record. No noise, no duplicate alerts.
Pricing
Free: 1 disease/keyword profile, daily email digest, ClinicalTrials.gov monitoring. No credit card required.
Starter — $49/month: 5 disease/keyword profiles, daily digest, phase and sponsor filters.
Pro — $149/month: Unlimited profiles, priority email delivery, digest frequency options. Best for BD teams and investors.